1. Hong Kong Stocks

  2. •

    Health technology

  3. •

    Pharmaceuticals: generic
JBM (Healthcare) Ltd.

JBM (Healthcare) Ltd.

HHKEX:2161
1.53
HKD
-0.07
(-4.37%)
2.18BMarket Cap
Nov 17Next Earn
JBM (Healthcare) Ltd.
HKEX:2161
(Hong Kong Exchange)

Recent

price

1.53

P/E

ratio

- -

div

yld

- -

ROIC.AI

2018
2019
2020
2021
2022
2023
2024
2025
2026
TTM
HKD
0.3
0.34
0.43
0.49
0.45
0.58
0.73
0.95
1.02
- -
Revenue per Share
0.05
0.06
0.05
0.03
0.03
0.06
0.15
0.24
0.25
- -
Basic EPS, GAAP
0.08
0.05
0.04
0.04
0.06
0.15
0.2
0.25
0.16
- -
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
0.01
0.06
0.1
0.21
- -
Dividend per Share
0.11
0.17
0.74
1.01
1.04
1.09
1.17
1.33
1.32
1.32
Book Value per Share
-0.56
-0.5
-0.22
0.05
0.1
0.13
0.14
0.32
0.04
0.04
Tangible Book Value per Share
894
894
894
814
894
891
884
819
817
815
Basic Weighted Avg Shares
264
308
382
397
406
520
648
782
835
- -
Sales/Revenue/Turnover
19.35
21.1
11.47
12.34
8.95
14
24.35
29.25
30.59
- -
Operating Margin (%)
30
30
36
44
48
44
47
52
50
- -
Depreciation Expense
42
52
41
23
25
57
130
197
201
- -
Net Income, GAAP
15.39
15.15
17.92
26.54
24.12
17.65
16.79
16.13
16.59
- -
Effective Tax Rate (%)
16.03
17.06
10.75
5.69
6.06
10.97
20.12
25.22
24.09
- -
Profit Margin (%)
-594
-669
170
147
136
136
146
171
231
231
Working Capital
12
8
447
195
137
77
51
9
259
259
LT Debt
121
178
715
947
969
1,031
1,022
1,164
1,131
1,131
Total Equity
- -
6.97
4.23
3.07
2.45
5.95
12.1
16.31
15.17
- -
Return on Invested Capital (%)
- -
5.79
3.83
1.67
2.57
4.81
11.05
15.7
14.1
- -
Return on Capital (%)
- -
42.86
10.19
2.89
2.68
5.96
13.34
19.22
18.6
- -
Return on Common Equity (%)

Capital Structure

HKD

•

in mil. unless spec.
Mar'25
Sep'26
Mar'26
ST Debt
163
36
134
LT Borrowings
- -
330
250
LT Finance Leases
9
9
9
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
814
817
820
Market Capitalization
1,457
2,444
2,181

Working Capital

HKD

•

in mil. unless spec.
Mar'25
Sep'26
Mar'26
Total Current Assets
452
542
488
Cash, Cash Equivalents & STI
206
194
120
Accounts Receivable, Net
134
207
229
Inventories
82
92
80
Total Current Liabilities
281
186
258
Payables & Accruals
- -
- -
- -
ST Debt
163
36
134
Deferred Revenue
- -
- -
- -

Growth Rates

HKD

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
3.78%
-2.83%
Free Cash Flow
- -
43.14%
-37.31%
Net Income, GAAP
- -
64.5%
1.94%
Sales/Revenue/Turnover
- -
16.47%
6.69%
Total Cash Common Dividend
- -
- -
120.85%

Semi-annual Revenue

HKD

•

in mil. unless spec.

Year

H1
H2
FY
2024
- -
- -
648
2025
- -
- -
782
2026
- -
- -
835

Semi-annual Earnings Per Share

HKD

•

in mil. unless spec.

Year

H1
H2
FY
2024
- -
- -
0.15
2025
- -
- -
0.24
2026
- -
- -
0.25

Semi-annual Dividends Per Share

HKD

•

in mil. unless spec.

Year

H1
H2
FY
2024
- -
- -
0.06
2025
- -
- -
0.1
2026
- -
- -
0.21
Similar Companies
Teva Pharmaceutical Industries Limited (NYSE:TEVA)
Teva Pharmaceutical Industries Limited (TASE:TEVA)
Jagsonpal Pharmaceuticals Ltd. (NSE:JAGSNPHARM)
Zim Laboratories Ltd. (NSE:ZIMLAB)
Paradigm Biopharmaceuticals Ltd. (ASX:PAR)
Neuren Pharmaceuticals Limited (ASX:NEU)
Business
JBM (Healthcare) Limited is an investment holding company engaged in the development, manufacturing, sourcing, distribution and marketing of branded healthcare and wellness products principally in Hong Kong, Macau, Mainland China and other markets in the Asia Pacific region. The company operates through three main segments offering Branded Medicines, which include medicines with chemical compounds as active ingredients; Proprietary Chinese Medicines, comprising registered Chinese herbal medicines such as Po Chai Pills (a leading gastrointestinal remedy with 120 years of tradition), Tong Tai Chung Woodlok Oil, Flying Eagle Woodlock Oil and Shiling Oil; and Health and Wellness Products, which encompass supplements, medical consumables, non-pharmaceutical items, over-the-counter medicines, medicated and non-medicated solutions and diagnostic devices. Founded in 2020 and headquartered at Units 808-811, 8th Floor, C-Bons International Centre, 108 Wai Yip Street, Kwun Tong, Kowloon, Hong Kong, JBM targets consumers seeking self-care solutions for health and well-being across Asia. Recent major developments include the completion of a 90% acquisition of Tin Hee Tong Medicine Factory, Limited in April 2025 to expand its proprietary Chinese medicines portfolio with the iconic Tin Hee Pills brand and planned marketing revitalization; entry into a sale and purchase agreement in June 2025 to acquire the entire share capital of Kenford Medical Group Company Limited for HK$38 million; a connected transaction in November 2024 involving the sale of shares in Li Chung Shing Tong (Holdings) Limited by subsidiaries Po Chai Herbal and PCHT to Europharm for HK$46.23 million; and a 2025 Europharm License Agreement announced in October 2025 alongside positive profit alerts and interim dividend declarations for the six months ended 30 September 2025.